首页> 外文期刊>Molecular & Cellular Toxicology >Specific elimination of coxsackievirus B3 infected cells with a protein engineered toxin-antitoxin system
【24h】

Specific elimination of coxsackievirus B3 infected cells with a protein engineered toxin-antitoxin system

机译:用蛋白质工程化毒素 - 抗毒素系统特异性消除Coxsackievirus B3感染细胞

获取原文
       

摘要

Coxsackievirus B3 (CVB3) is a member of the family Picornaviridae, and along with polio-viruses, belongs to the Enterovirus genus. The CVB3 genome is composed single-stranded RNA encoding polyproteins, which are cleaved to individual functional proteins by 2A and 3C proteases proteins which have been targeted for drug development. Here, we showed that protease activity required to activate a toxic protein may be used to prevent viral infection. We modified the MazE-MazF antitoxin-toxin system of Escherichia coli to fuse a C-terminal fragment of MazE to the N-terminal end of toxin MazF with a linker having a specific protease cleavage site for CVB3. This fusion protein formed a stable dimer and was capable of inactivating the mRNA interferase activity of MazF which cleaves the ACA sequence in mRNA substrates. The incubation of 2A proteases with the fusion proteins induced cleavage between the MazE and MazF fragments from the fusion proteins; the subsequent release of MazF significantly inhibited virus replication. Additionally, we note that, CVB3 infected HeLa cells quickly died through a MazF toxin mediated effect before virus protein expression. These findings suggest that the MazEF fusion protein has a strong potential to be developed as an anti-virus therapy following CVB3 infection.
机译:Coxsackievirus B3(CVB3)是Picornaviridae家族的成员,以及脊髓灰质病毒,属于肠道病毒属。 CVB3基因组被组成单链RNA编码的多蛋白,其通过2A和3C蛋白酶蛋白切割成单独的官能蛋白,该蛋白已针对药物发育。在此,我们表明,可用于防止有毒蛋白质所需的蛋白酶活性来预防病毒感染。我们修饰了大肠杆菌的迷宫 - Mazf抗毒素 - 毒素系统,将迷宫的C末端片段熔化到毒素MAZF的N-末端结束,其中具有用于CVB3的特定蛋白酶切割位点的接头。该融合蛋白形成稳定的二聚体,并且能够灭活MAZF的mRNA干扰酶活性,其在mRNA底物中切割ACA序列。将融合蛋白与融合蛋白的迷宫和MAZF碎片之间的培养与融合蛋白质诱导切割;随后的MAZF释放显着抑制病毒复制。此外,我们注意到,CVB3感染的HeLa细胞通过在病毒蛋白表达之前通过MAZF毒素介导的效果迅速死亡。这些研究结果表明,MAZEF融合蛋白具有强烈的潜力,才能在CVB3感染后作为抗病毒治疗发展。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号